Celcuity Q1 FY26 net loss widens 43% to $52.84 million

Celcuity Inc.

Celcuity Inc.

CELC

0.00
  • Celcuity posted a net loss of USD 52.8 million for the quarter ended March 31, 2026, widening 43% from the year-earlier period.
  • Operating loss widened to USD 50.5 million as total operating expenses climbed 40% to USD 50.51 million.
  • Research and development expense rose 11% to USD 33.06 million, while selling, general and administrative costs more than doubled to USD 17.44 million.
  • Cash, cash equivalents and short-term investments totaled USD 387.1 million at March 31, 2026; net cash used in operating activities increased to USD 55.07 million from USD 35.85 million a year earlier.
  • FDA accepted for filing Celcuity’s NDA for gedatolisib in HR+/HER2- PIK3CA wild-type advanced breast cancer, granting Priority Review with a PDUFA goal date of July 17, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023180), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.